The global implantable drug delivery devices market size is expected to reach USD 31.6 billion by 2025

LONDON, June 26, 2018 /PRNewswire/ -- Implantable Drug Delivery Devices Market Analysis Report By Type (Biodegradable, Non-biodegradable), By Product, By Technology (Diffusion, Osmotic, Magnetic), By Application, And Segment Forecasts, 2018 - 2025

Download the full report: https://www.reportbuyer.com/product/5445437

The global implantable drug delivery devices market size is expected to reach USD 31.6 billion by 2025 registering a 7.5% CAGR during the forecast period. Growing incidence of chronic diseases, coupled with rising demand for minimally invasive treatment options, is driving the market for implantable drug delivery devices.

Recent advancements in medication administration technologies are expected to fuel market growth over the forecast period.Increase in adoption of micro-scale implantable devices is one of the key factors fueling growth.

These products find application in monitoring improvement in body functions, imaging, and medication administration. They facilitate localized treatment with controlled drug administration and enable targeted delivery of therapeutics to tissues.

These devices help overcome limitations of intravenous, oral, and topical administration routes, thus broadening the growth prospects of the market.In addition, advent of biodegradable implants enables targeted delivery of chemotherapeutics to tumor cells without damaging normal cells.

Drug releasing implants are also helpful in treatment of inoperable tumors such as that of liver, brain, and lungs, due to their location and size.These devices help in reducing tumor size, which enables surgical removal of tumors.

The aforementioned benefits of these devices are expected to impel their adoption over the forecast period.

Manufacturers are focused on developing novel drug delivery devices to gain maximum market share, which has resulted in launch of various technologically advanced products in the market. For instance, in February 2017, Delpor, Inc., a biotechnology company in U.S., announced the launch of an implantable device for long-term delivery of therapeutics.

Further key findings from the report suggest:
• By product, drug-eluting stents held a dominant share in the market in 2016, owing to their growing adoption in hormone regulation, contraception, pain management, and cancer therapy. Bio-absorbable stents, on the other hand, are anticipated to grow at a lucrative rate owing to increase in incidence of peripheral and coronary artery diseases
• On the basis of type, the non-biodegradable segment held the largest share in 2016, as a consequence of easy availability of these products and their established efficacy
• Diffusion held a dominant share in the market on the basis of technology, owing to significant increase in adoption as it offers better patient outcomes and acceptability
• By application, cardiovascular accounted for a substantial share in 2016 due to increasing adoption of drug-eluting and bio-absorbable stents for management of cardiovascular diseases. Autoimmune diseases, on the other hand, are expected to exhibit the fastest CAGR owing to rising prevalence of multiple sclerosis and rheumatoid arthritis
• While North America held a substantial share in 2016 owing to rising prevalence of chronic diseases, unhealthy lifestyles, and high stress levels among the population, Asia Pacific is anticipated to achieve significant CAGR through 2025. This is owing to improving healthcare systems, rising healthcare expenditure, and growing awareness.

Download the full report: https://www.reportbuyer.com/product/5445437

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

SOURCE ReportBuyer

Related Links

http://www.reportbuyer.com